136 active not recruiting. 136 Phase 2, 43 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 136 | Active not recruiting 136 |
| Phase 1 | 43 | Active not recruiting 43 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Pirtobrutinib - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Eli Lilly and Company | 13 | 2025-08-07 | 2026-04-17 |
| A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | BeOne Medicines | 94 | 2024-11-14 | 2026-07-09 |
| Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program Daratumumab plus chemotherapy according to the national treatment program - T-Lymphocytic Leukemia, Acute | Phase 2 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 31 | 2024-10-17 | 2026-03-05 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period Venetoclax, cBTKi Monotherapy - Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Genentech, Inc. | 118 | 2024-08-09 | 2026-09-28 |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia Ibrutinib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 333 | 2024-05-30 | 2026-11-03 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| A Study of BN104 in the Treatment of Acute Leukemia BN104 monotherapy, BN104 monotherapy - rp2d - ALL, Adult, AML, Adult | Phase 1 / Phase 2 | Active not recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | 66 | 2023-10-19 | 2026-02-25 |
| A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies GNC-035 - Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 3 | 2023-08-16 | 2025-09-26 |
| Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL VenObi+Ven or VenObi+VenZan - High Risk CLL, Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 78 | 2023-07-21 | 2026-03-17 |
| Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia Cyclophosphamide, Vincristine, Dexamethasone - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 68 | 2023-06-09 | 2026-07-10 |
| A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) BEAM-201 - Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Beam Therapeutics Inc. | 5 | 2023-05-25 | 2025-01-13 |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 26 | 2023-05-18 | 2026-10-01 |
| Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 50 | 2023-05-08 | 2026-02-25 |
| Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 72 | 2023-01-31 | 2026-02-12 |
| Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Durvalumab, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 2 | Active not recruiting | Mayo Clinic | 27 | 2023-01-05 | 2026-10-05 |
Showing 20 of 136. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (66) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (63) · Leukemia, Myeloid, Acute (25) · Leukemia (20) · Myelodysplastic Syndromes (20) · Lymphoma, Non-Hodgkin (15) · Lymphoma (14) · Recurrence (11) · Leukemia, Biphenotypic, Acute (10) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Lymphoma, Mantle-Cell (10) · Burkitt Lymphoma (9) · Hodgkin Disease (9) · Leukemia, B-Cell (9) · Myeloproliferative Disorders (9)
Hemic and Lymphatic Diseases (136) · Lymphatic Diseases (133) · Hematologic Diseases (132) · Immune System Diseases (132) · Immunoproliferative Disorders (132) · Neoplasms by Histologic Type (132) · Lymphoproliferative Disorders (129) · Neoplasms (128) · Leukemia (116) · Pathologic Processes (83) · Pathological Conditions, Signs and Symptoms (83) · Disease Attributes (82) · Chronic Disease (76) · Leukemia, B-Cell (62)
Cyclophosphamide (40) · venetoclax (27) · fludarabine (19) · fludarabine phosphate (17) · Vincristine (16) · Methotrexate (15) · Rituximab (15) · ibrutinib (15) · acalabrutinib (13) · blinatumomab (13) · Cytarabine (12) · Doxorubicin (11) · obinutuzumab (11) · Dexamethasone (10) · Melphalan (10)
M.D. Anderson Cancer Center (16) · City of Hope Medical Center (12) · Memorial Sloan Kettering Cancer Center (8) · St. Jude Children's Research Hospital (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (5) · Dana-Farber Cancer Institute (4) · Acerta Pharma BV (3) · Fred Hutchinson Cancer Center (3) · Genmab (3) · National Cancer Institute (NCI) (3) · AbbVie (2) · Bellicum Pharmaceuticals (2) · Center for International Blood and Marrow Transplant Research (2) · Children's Oncology Group (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2)
United States (105) · Italy (18) · France (14) · Spain (14) · Canada (13) · China (12) · Germany (11) · Australia (10) · United Kingdom (9) · Japan (8) · Belgium (6) · Netherlands (6) · Czechia (5) · Israel (5) · Poland (5)
Elias Jabbour (3) · Jan A Burger (3) · Meghan Thompson, MD (3) · Nitin Jain (3) · Andy Itsara, M.D. (2) · Anjali S Advani (2) · Brandon Triplett, MD (2) · John Allan, M.D. (2) · Kerry Rogers, MD (2) · Matthew Davids, MD (2)
PMID 41671463, PMID 27503501, PMID 28714866, PMID 34398557, PMID 34515338, PMID 34608724, PMID 35622074, PMID 42411504, PMID 42541678, PMID 24327518, PMID 24659631, PMID 24699307, PMID 25555420, PMID 26182309, PMID 26337493, PMID 26430171, PMID 26432046, PMID 26641137, PMID 26907630, PMID 26982511, PMID 27424289, PMID 27601462, PMID 27760761, PMID 28049639, PMID 28053024, PMID 28089238, PMID 28408462, PMID 28672195, PMID 29358183, PMID 29383130, PMID 29483101, PMID 29618479, PMID 29846250, PMID 30111609, PMID 30405781, PMID 30501869, PMID 30530801, PMID 30860496, PMID 30938714, PMID 30975030, PMID 31076409, PMID 31088809, PMID 31101621, PMID 31141631, PMID 31208944, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31876911, PMID 31882719
P30CA033572 (7), 2023 (6), U10CA180888 (3), 2017 (2), 2018 (2), P30CA015704 (2), U10CA180886 (2), 2014 (1), 2015 (1), N01CM00070 (1), N01CM62207 (1), P01CA018029 (1), P01CA095426 (1), P30CA016058 (1), P50CA140158 (1)